EVENTS · PODD
PEERS
EARNINGS
Insulet Corporation is a medical device company focused on insulin delivery and diabetes management. Its flagship Omnipod platform includes wearable, tubeless insulin management systems designed to deliver continuous insulin without traditional pump tubing or multiple daily injections. The product line includes Omnipod 5, Omnipod DASH, and the Classic Omnipod, along with related pods, controllers, and diabetes management software that support day-to-day glucose control. Insulet also works with selected partners to adapt its Pod technology for the subcutaneous delivery of non-insulin therapies in other medical areas. Headquartered in Acton, Massachusetts, Insulet serves patients and healthcare providers across multiple international markets through direct sales and distribution channels.
Insulet jumped after third quarter revenue rose about a fifth and profit more than doubled from a year earlier
Wed| Series | 1W | 1M |
|---|---|---|
| PODD | +10.8% | +22.5% |
| Peers | +5.0% | +13.2% |
| Sector · Health Care | +5.7% | +13.6% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 85 | 93 |
The board authorized a share repurchase program.
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 1.59 | 1.99 | +25.16% | — |
| Q2 FY2026 | 1.48 | 1.66 | +12.20% | −16.50% |
| Q1 FY2026 | 1.22 | 1.42 | +16.19% | −4.26% |
| Q4 FY2025 | 1.48 | 1.55 | +4.50% | +1.12% |
| Q3 FY2025 | 1.16 | 1.24 | +6.50% | +1.71% |
| Series | 1W | 1M |
|---|---|---|
| PODD | +10.8% | +22.5% |
| Peers | +5.0% | +13.2% |
| Sector · Health Care | +5.7% | +13.6% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 85 | 93 |
